Literature DB >> 3021804

Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies.

P M Keller, K Lonergan, B J Neff, D A Morton, R W Ellis.   

Abstract

We have utilized monoclonal antibodies in immune affinity chromatography to purify each of the 3 major glycoproteins of varicella-zoster virus (VZV), gpI, gpII, and gpIII, in immunologically active form. Upon injection into guinea pigs, each preparation elicited the production of specific antibodies capable of immunoprecipitating the homologous glycoprotein and of neutralizing VZV infectivity in vitro. Also, total glycoproteins from VZV-infected cells have been purified by lectin affinity chromatography. Each of the individual purified glycoproteins, as well as total VZV glycoproteins and appropriate uninfected cell protein controls, have been employed as solid-phase reagents in enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies directed against specific VZV glycoproteins. The specificity of the purified glycoproteins as ELISA reagents was verified by the ability of individual monoclonal antibodies to bind specifically to individual glycoprotein preparations. We have demonstrated the utility of the glycoprotein-specific ELISA by detecting antibodies in sera from post-zoster and post-varicella patients. The assay detects antibodies directed against each of the 3 major glycoproteins and is sensitive enough to detect antibodies in a 1:320 000 dilution of some sera. This assay, as well as the purified individual glycoproteins per se, should prove to be very useful reagents in understanding the role of each of gpI, gpII, and gpIII in immunity to VZV.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021804     DOI: 10.1016/0166-0934(86)90048-0

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  10 in total

1.  A double-blind, randomized, multicenter, controlled study to evaluate the immunogenicity, safety, and tolerability of varicella vaccine (VARIVAX™) passage extension 34 (PE34) process administered concomitantly with measles, mumps, and rubella vaccine (M-M-R™ II).

Authors:  Peter E Silas; Edward N Zissman; Julie Gardner; Shanjun Helian; Andrew W Lee; Heather L Platt
Journal:  Hum Vaccin Immunother       Date:  2020-05-19       Impact factor: 3.452

2.  Varicella-zoster virus (VZV) glycoprotein E is a serological antigen for detection of intrathecal antibodies to VZV in central nervous system infections, without cross-reaction to herpes simplex virus 1.

Authors:  Anna Grahn; Marie Studahl; Staffan Nilsson; Elisabeth Thomsson; Malin Bäckström; Tomas Bergström
Journal:  Clin Vaccine Immunol       Date:  2011-06-22

3.  Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer.

Authors:  Michael J Boeckh; Ann M Arvin; Kathleen M Mullane; Luis H Camacho; Drew J Winston; Vicki A Morrison; Kimberly Hurtado; Jessie Durrand Hall; Lei Pang; Shu-Chih Su; Susan S Kaplan; Paula W Annunziato; Zoran Popmihajlov
Journal:  Open Forum Infect Dis       Date:  2020-06-02       Impact factor: 3.835

Review 4.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

5.  Reactivity of varicella-zoster virus subunit antigens in enzyme-linked immunosorbent assay to sera from varicella, zoster, and herpes simplex virus infections.

Authors:  M Takayama
Journal:  Med Microbiol Immunol       Date:  1994-02       Impact factor: 3.402

6.  Specific lysis of targets expressing varicella-zoster virus gpI or gpIV by CD4+ human T-cell clones.

Authors:  Z Huang; A Vafai; J Lee; R Mahalingam; A R Hayward
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

7.  A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.

Authors:  Gary S Marshall; Shelly D Senders; Julie Shepard; Jerry D Twiggs; Julie Gardner; Darcy Hille; Jonathan Hartzel; Rowan Valenzuela; Jon E Stek; Frans A Helmond
Journal:  Hum Vaccin Immunother       Date:  2016-05-05       Impact factor: 3.452

8.  Evaluation of a commercial glycoprotein enzyme-linked immunosorbent assay for measuring vaccine immunity to varicella.

Authors:  Yun Hwa Kim; Ji Young Hwang; Hye Min Shim; Eunsil Lee; Songyong Park; Hosun Park
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

9.  Serological Evaluation of Immunity to the Varicella-Zoster Virus Based on a Novel Competitive Enzyme-Linked Immunosorbent Assay.

Authors:  Jian Liu; Xiangzhong Ye; Jizong Jia; Rui Zhu; Lina Wang; Chunye Chen; Lianwei Yang; Yongmei Wang; Wei Wang; Jianghui Ye; Yimin Li; Hua Zhu; Qinjian Zhao; Tong Cheng; Ningshao Xia
Journal:  Sci Rep       Date:  2016-02-08       Impact factor: 4.379

10.  Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial.

Authors:  Yves Gillet; Pirmin Habermehl; Stéphane Thomas; Cécile Eymin; Anne Fiquet
Journal:  BMC Med       Date:  2009-04-14       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.